A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 21 Jul 2019 Planned End Date changed from 1 Jul 2022 to 1 Feb 2023.
- 21 Jul 2019 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2022.
- 21 Jul 2019 Status changed from not yet recruiting to recruiting.